Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for nAMD, DME, and RVO
NCT06572553Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Mar 2024; status: recruiting.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT06572553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572553.